Skip to content
lifestyle.chroniccities.us
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Tech
Travel
Author:
Accro Bioscience (Suzhou) Limited
Accro Bioscience Announces First Patient Dosed in Phase IIb Study of AC-101 in Moderate-to-Severe Ulcerative Colitis
September 20, 2026
Accro Bioscience Announces Inclusion of AC-101 tablets in the NMPA CDE’s “Caring Plan-Extension” Pilot Program for Rare Disease Drug Development
September 13, 2026
AC-201 for Vitiligo: Accro Bioscience Secures IND Clearance for Trials
September 8, 2026